

Ready for Your Patients With Alpha₁-Antitrypsin Deficiency

GLASSIA® [Alpha₁-Proteinase Inhibitor (Human)] Injection and ARALAST® NP [Alpha₁-Proteinase Inhibitor (Human)] are available for your patients from specialty pharmacy providers (SPPs). Work with your patients to determine which SPP might be right for them.

The following SPPs are currently authorized to dispense GLASSIA and ARALAST NP:

Accredo® Specialty Pharmacy

CenterWell Specialty Pharmacy™

AIS Healthcare®

CVS Health®

Amerita Specialty Infusion Services

Option Care Health®

AvevoRX

Optum® Infusion Pharmacy

BioPlus® Specialty Pharmacy

Walgreens Specialty Pharmacy



For more information about GLASSIA or ARALAST NP, please contact your Takeda representative.

INDICATION AND LIMITATIONS OF USE:

GLASSIA and **ARALAST NP** are Alpha₁-Proteinase Inhibitors (Human) (Alpha₁-PI) indicated for chronic augmentation therapy in adults with clinically evident emphysema due to severe hereditary deficiency of Alpha₁-PI (alpha₁-antitrypsin deficiency). **ARALAST NP** increases antigenic and functional (antineutrophil elastase capacity [ANEC]) serum levels and antigenic lung epithelial lining fluid levels of Alpha₁-PI.

- The effect of augmentation therapy with **GLASSIA**, **ARALAST NP**, or any Alpha₁-PI product on pulmonary exacerbations and on the progression of emphysema in Alpha₁-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials
- Clinical data demonstrating the long-term effects of chronic augmentation and maintenance therapy of individuals with **GLASSIA** or **ARALAST NP** are not available
- **GLASSIA** and **ARALAST NP** are not indicated as therapies for lung disease in patients in whom severe Alpha₁-PI deficiency has not been established

IMPORTANT SAFETY INFORMATION

Contraindications

- Immunoglobulin A (IgA) deficient patients with antibodies against IgA
- History of anaphylaxis or other severe systemic reaction to Alpha₁-PI products.

Please see additional Important Safety Information throughout and click for Full Prescribing Information for **GLASSIA** and **ARALAST NP**

Two Alpha₁-Proteinase Inhibitor Options to Fit Your Patients' Needs

Glassia

[Alpha₁-Proteinase Inhibitor (Human)]

GLASSIA® [Alpha₁-Proteinase Inhibitor (Human)] Is Ready to Use

Each carton of GLASSIA contains a single-dose vial containing approximately 1 gram (1000 mg) of functional Alpha₁-PI in 50 mL of ready-to-use solution.¹

1 gram¹: NDC 0944-2884-01

HCPCS Code²: J0257

Injection, Alpha₁-proteinase inhibitor (human), (GLASSIA), 10 mg

Aralast NP

[Alpha₁-Proteinase Inhibitor (Human)]

ARALAST® NP [Alpha₁-Proteinase Inhibitor (Human)] Is a Lyophilized Powder for Reconstitution

Each kit of ARALAST NP contains a single-dose vial of 0.5 gram or 1 gram of functional Alpha₁-PI, a suitable volume of sterile water for injection, USP diluent (25 mL for 0.5 gram vial; 50 mL for 1 gram vial), one sterile double-ended transfer needle, and one sterile 20 micron filter needle.³

0.5 gram³: NDC 0944-2814-01

1 gram³: NDC 0944-2815-01

HCPCS Code²: J0256

Injection, Alpha₁-proteinase inhibitor (human), not otherwise specified, 10 mg

HCPCS, Healthcare Common Procedure Coding System; NDC, National Drug Code; USP, United States Pharmacopoeia.



For direct ordering information about GLASSIA or ARALAST NP, please contact Takeda Customer Care at 800-423-2090.

IMPORTANT SAFETY INFORMATION, Continued

Warnings and Precautions

Hypersensitivity: **GLASSIA** and **ARALAST NP** may contain trace amounts of IgA. Patients with known antibodies to IgA have a greater risk of developing severe hypersensitivity and anaphylactic reactions. Closely follow the recommended infusion rate, monitor vital signs continuously, and observe the patient throughout the infusion. If hypersensitivity symptoms occur, discontinue the infusion and administer appropriate emergency treatment. Have epinephrine and/or other appropriate supportive therapy available for any acute anaphylactic or anaphylactoid reaction.

Please see additional Important Safety Information throughout and click for Full Prescribing Information for **GLASSIA** and **ARALAST NP**



Patient Support

Your Source for Education and Access



Tailored support for your patients prescribed Alpha₁ augmentation therapy

After you and your patient choose a treatment path, Takeda Patient Support is here with a range of personalized services for them.

We know living with Alpha₁-antitrypsin deficiency looks different for everyone. Whether they've just been diagnosed or have been on treatment for a long time, we get to know your patient. We work to understand who they are, and we learn what's most important to them—so we can provide the support they need when it comes to their treatment.

From the moment they enroll, dedicated support specialists will work with them.

When you prescribe GLASSIA® [Alpha₁-Proteinase Inhibitor (Human)] or ARALAST® NP [Alpha₁-Proteinase Inhibitor (Human)] for your patient, Takeda Patient Support is here for them. Our support specialists can address your patient's questions and concerns and help get them the information they need.

For onboarding, access, and reimbursement assistance, our services include:

- 🔄 **Benefits investigation** to help determine your patient's insurance benefits and eligibility for certain services
- 🔄 **Prior authorization (PA), reauthorization, and appeals information**
- 🔄 **Enrollment into the Takeda Patient Support Co-Pay Assistance Program** if they qualify*
- 🔄 **Information about financial assistance options** if they're eligible

Our additional services include:

- 🔄 **Specialty pharmacy (or site of care) triage** and coordination
- 🔄 **Takeda product infusion training** for healthcare providers, as well as **home treatment support and education** for your patient
- 🔄 **Arranging** for a trained nursing professional to teach your patient how to infuse treatment at home, if requested by your office (if available)
- 🔄 **Directing your patient** to community support resources

Want to connect?

Our support specialists are never more than a tap or a call away—

1-866-888-0660, Monday through Friday, 8:30 AM to 8 PM ET.

If English is not your patient's preferred language, Takeda Patient Support can communicate with them over the phone using a translation service.

How to get your patient started on GLASSIA or ARALAST NP:

1. Complete and sign the Start Form
2. Have your patient sign the Patient Authorization section
3. Takeda Patient Support will review the Start Form and confirm patient eligibility
4. Your patient will then receive a welcome call from their dedicated support specialist
5. The support specialist will get them started with Takeda Patient Support

Need to enroll your patient?

Click below to visit our convenient online enrollment portal at takedapatientssupport.com/hcp.

You can also enroll your patient by faxing the completed Start Form to **1-844-755-5751**.

To learn more about Takeda Patient Support, visit: www.takedapatientssupport.com/hcp

*To be eligible, your patient must be enrolled in Takeda Patient Support and have commercial insurance. Other terms and conditions apply. Call us for more details.

IMPORTANT SAFETY INFORMATION, Continued

Warnings and Precautions, Continued

Transmissible Infectious Agents: Because **GLASSIA** and **ARALAST NP** are made from human plasma, they may carry a risk of transmitting infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD), and theoretically the Creutzfeldt-Jakob disease (CJD) agent and other pathogens. No seroconversions for hepatitis B or C or human immunodeficiency virus or any other known infectious agent were reported with the use of **GLASSIA** or **ARALAST NP** during the clinical trials.

Adverse Reactions

GLASSIA: The serious adverse reaction observed during clinical trials was exacerbation of chronic obstructive pulmonary disease (COPD). The most common adverse reactions during clinical trials were headache and upper respiratory infection.

ARALAST NP: Hypersensitivity reactions have been reported in patients following administration of **ARALAST NP**. The most common adverse reactions occurring in $\geq 5\%$ of infusions in clinical trials were headache, musculoskeletal discomfort, vessel puncture site bruise, nausea, and rhinorrhea.

Please click for [Full Prescribing Information for **GLASSIA** and **ARALAST NP**](#).

References: **1.** GLASSIA [Alpha₁-Proteinase Inhibitor (Human)] Injection Solution, prescribing information. Lexington, MA: Baxalta US Inc. September 2023. **2.** Centers for Medicare & Medicaid Services. April 2024 Alpha-Numeric HCPCS. March 5, 2024. Accessed March 6, 2024. <https://www.cms.gov/medicare/coding/hcpcsreleasecodesets/hcpcs-quarterly-update> **3.** ARALAST NP [Alpha₁-Proteinase Inhibitor (Human)], prescribing information. Lexington, MA: Baxalta US Inc. March 2023.



©2024 Takeda Pharmaceuticals U.S.A., Inc., 500 Kendall St, Cambridge, MA 02142. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA®, the TAKEDA Logo®, and the Takeda Patient Support logo™ are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. ARALAST® and the ARALAST Logo® are registered trademarks of Baxalta Incorporated, a Takeda company. GLASSIA® and the GLASSIA Logo® are registered trademarks of Kamada Ltd., and used under license.

US-XMP-2723v1.0 04/24